HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting.

AbstractBACKGROUND:
Genetic evidence for diversifying selection identified the Merozoite Surface Protein1 block2 (PfMSP1 block2) as a putative target of protective immunity against Plasmodium falciparum. The locus displays three family types and one recombinant type, each with multiple allelic forms differing by single nucleotide polymorphism as well as sequence, copy number and arrangement variation of three amino acid repeats. The family-specific antibody responses observed in endemic settings support immune selection operating at the family level. However, the factors contributing to the large intra-family allelic diversity remain unclear. To address this question, population allelic polymorphism and sequence variant-specific antibody responses were studied in a single Senegalese rural community where malaria transmission is intense and perennial.
RESULTS:
Family distribution showed no significant temporal fluctuation over the 10 y period surveyed. Sequencing of 358 PCR fragments identified 126 distinct alleles, including numerous novel alleles in each family and multiple novel alleles of recombinant types. The parasite population consisted in a large number of low frequency alleles, alongside one high-frequency and three intermediate frequency alleles. Population diversity tests supported positive selection at the family level, but showed no significant departure from neutrality when considering intra-family allelic sequence diversity and all families combined. Seroprevalence, analysed using biotinylated peptides displaying numerous sequence variants, was moderate and increased with age. Reactivity profiles were individual-specific, mapped to the family-specific flanking regions and to repeat sequences shared by numerous allelic forms within a family type. Seroreactivity to K1-, Mad20- and R033 families correlated with the relative family genotype distribution within the village. Antibody specificity remained unchanged with cumulated exposure to an increasingly large number of alleles.
CONCLUSION:
The Pfmsp1 block2 locus presents a very large population sequence diversity. The lack of stable acquisition of novel antibody specificities despite exposure to novel allelic forms is reminiscent of clonal imprinting. The locus appears under antibody-mediated diversifying selection in a variable environment that maintains a balance between the various family types without selecting for sequence variant allelic forms. There is no evidence of positive selection for intra-family sequence diversity, consistent with the observed characteristics of the antibody response.
AuthorsNitchakarn Noranate, Franck Prugnolle, Hélène Jouin, Adama Tall, Laurence Marrama, Cheikh Sokhna, Marie-Thérèse Ekala, Micheline Guillotte, Emmanuel Bischoff, Christiane Bouchier, Jintana Patarapotikul, Jun Ohashi, Jean-François Trape, Christophe Rogier, Odile Mercereau-Puijalon
JournalBMC microbiology (BMC Microbiol) Vol. 9 Pg. 219 (Oct 15 2009) ISSN: 1471-2180 [Electronic] England
PMID19832989 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Protozoan
  • DNA, Protozoan
  • Merozoite Surface Protein 1
Topics
  • Adolescent
  • Adult
  • Alleles
  • Animals
  • Antibodies, Protozoan (blood)
  • Child
  • Child, Preschool
  • DNA, Protozoan (genetics)
  • Follow-Up Studies
  • Gene Frequency
  • Genetics, Population
  • Genotype
  • Humans
  • Infant
  • Malaria, Falciparum (epidemiology, immunology)
  • Merozoite Surface Protein 1 (genetics)
  • Plasmodium falciparum (genetics, immunology)
  • Polymorphism, Genetic
  • Seasons
  • Selection, Genetic
  • Senegal (epidemiology)
  • Sequence Analysis, DNA
  • Seroepidemiologic Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: